Eli Lilly and Company $LLY Shares Sold by South Street Advisors LLC

South Street Advisors LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 2.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 27,161 shares of the company’s stock after selling 773 shares during the quarter. Eli Lilly and Company accounts for approximately 4.2% of South Street Advisors LLC’s investment portfolio, making the stock its 7th biggest holding. South Street Advisors LLC’s holdings in Eli Lilly and Company were worth $32,578,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $25,000. Basso Capital Management L.P. purchased a new position in Eli Lilly and Company during the fourth quarter valued at approximately $30,000. E Fund Management Hong Kong Co. Ltd. raised its position in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after acquiring an additional 24 shares in the last quarter. New England Capital Financial Advisors LLC lifted its holdings in Eli Lilly and Company by 142.9% in the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares during the period. Finally, Maseco LLP boosted its position in Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 3.7%

Eli Lilly and Company stock opened at $1,227.11 on Wednesday. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock has a market capitalization of $1.16 trillion, a PE ratio of 41.18, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51. The business has a 50 day simple moving average of $1,173.20 and a 200-day simple moving average of $1,055.15. Eli Lilly and Company has a 12 month low of $685.15 and a 12 month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter last year, the firm posted $6.31 EPS. The business’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts anticipate that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 23.22%.

Insider Activity

In related news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 over the last 90 days. 0.14% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on LLY. Wolfe Research reaffirmed an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Morgan Stanley reiterated an “overweight” rating and issued a $1,419.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 6th. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a report on Friday, August 7th. Finally, Bank of America upped their price objective on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,292.18.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Weight-loss leadership remains a key catalyst. Eli Lilly was highlighted as an IBD Stock of the Day as its obesity-drug business gains ground on Novo Nordisk. Investor attention is also focused on the company’s next-generation obesity candidate retatrutide following encouraging trial-related developments. Eli Lilly, Stock Of The Day, Is Erasing Novo’s Early Lead In Weight-Loss Pills
• Positive Sentiment: Recent quarterly results support the bullish outlook. Lilly’s latest reported quarter substantially exceeded earnings and revenue expectations, with revenue up 47.7% year over year. Analysts cited GLP-1 momentum, a broad pipeline and strong operating growth as reasons for continued long-term momentum. LLY Up Around 6% Post Robust Q2 Results
• Positive Sentiment: Pipeline expansion continued through partnerships. Lilly signed a global collaboration and licensing agreement with OmniAb for an ion-channel drug-discovery program, potentially providing access to new medicines. It also made a $10 million upfront payment to AlzeCure for rights connected to small-molecule CNS treatments, including Alzheimer’s and pain candidates. OmniAb Enters Collaboration and License Agreement with Eli Lilly
• Neutral Sentiment: International execution is progressing. Lilly appointed Tayllit Aherdan to lead operations in the United Arab Emirates, Qatar and Kuwait, supporting its commercial expansion in the Middle East. Lilly Appoints Tayllit Aherdan
• Negative Sentiment: Valuation and competition remain risks. Analysts noted that Lilly’s premium valuation leaves less room for execution misses, while competition, pricing pressure and future obesity-drug rivals could moderate upside.
• Negative Sentiment: An executive sale adds a minor sentiment headwind. EVP Patrik Jonsson sold 6,500 shares worth approximately $7.6 million. However, the transaction was made under a pre-arranged Rule 10b5-1 plan, reducing its significance as a discretionary bearish signal. SEC Insider Transaction Filing

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.